Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language. Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.
Latest from Lisa Takagi
Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.
Japan's government has already allocated more than $400m to repatriate manufacturing of important drugs and continues to provide support as it expands a list of "national security" drugs.
Along with multiple new therapeutics for NSCLC, Astellas's Izervay and several products licensed from US companies receive approval recommendations in Japan.
Under new owner Bain Capital, the Japanese firm is aiming to regain its global presence, helped by new top executives formerly with Pfizer Japan and Takeda.
Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.
Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.